NCT06789666 Digital Art Therapy for Young Cancer Survivors
| NCT ID | NCT06789666 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2025-04-07 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-site, single-arm, interventional study assessing the feasibility of the ARTCan Therapy Application (App) and whether it is an acceptable means of administering art therapy to young adult cancer survivors. The ARTCan Therapy App guides participants through a 6-week digital art therapy program. Subjects will participate in weekly art therapy prompts guided by the app and will complete weekly mental health quality of life (MHQoL) surveys during the intervention. In addition, baseline and end-of-intervention patient-reported outcome measures (PROMIS-DSF8a) and an acceptability survey will be administered. The hypothesis is that digital art therapy is feasible for young adult cancer survivors with self-reported mood issues and is an acceptable means of administering art therapy in the patient population.
Eligibility Criteria
Inclusion Criteria: In order to participate in this study a subject must meet all of the eligibility criteria outlined below. * Written informed assent and parental consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Subject is willing and able to comply with study procedures based on the judgment of the investigator. * Age 18-25 years at the time of consent. * Childhood cancer survivor, defined as having cancer between birth 17 years of age and who has completed cancer treatment. * Reliable internet connection and access to a computer, smartphone, or iPad to support application and virtual study visits. * Answers "yes" to the question "Do you experience mood issues (yes or no)?". Exclusion Criteria: * All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation. * Patients who lack interest in art. Screening question: Are you open to making art on a scale from 1-5 (1 being not at all, and 5 being very much; must score 3 or higher). * Subjects who lack basic technology skills (Screening question: On a scale of 1-5 (1 being uncomfortable, and 5 being very comfortable), how would you rate your comfort using websites. Must score 3 or higher). * Subjects unable to provide consent. * Other conditions or factors which in the opinion of the Pl would not make the patient a good candidate for the study.
Contact & Investigator
Soma Sengupta, MD
PRINCIPAL INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06789666 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06789666 currently recruiting?
Yes, NCT06789666 is actively recruiting participants. Contact the research team at devin_mccarthy@med.unc.edu for enrollment information.
Where is the NCT06789666 trial being conducted?
This trial is being conducted at Chapel Hill, United States.
Who is sponsoring the NCT06789666 clinical trial?
NCT06789666 is sponsored by UNC Lineberger Comprehensive Cancer Center. The principal investigator is Soma Sengupta, MD at UNC Lineberger Comprehensive Cancer Center. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.